Cargando…
Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
PURPOSE: Intravitreal (IVT) injections of the anti-vascular endothelial growth factor (VEGF) agents aflibercept, bevacizumab, and ranibizumab are commonly prescribed to treat neovascular age-related macular degeneration (nAMD). Studies comparing inflammation rates in large populations of patients re...
Autores principales: | Kiss, Szilárd, Dugel, Pravin U, Khanani, Arshad M, Broder, Michael S, Chang, Eunice, Sun, Gordon H, Turpcu, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124467/ https://www.ncbi.nlm.nih.gov/pubmed/30214147 http://dx.doi.org/10.2147/OPTH.S169143 |
Ejemplares similares
-
Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections
por: Lau, P. ET., et al.
Publicado: (2018) -
Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics
por: Morioka, Masakazu, et al.
Publicado: (2020) -
Bacterial endophthalmitis following anti-VEGF intravitreal injections: a retrospective case series
por: Bergamo, Vinicius Campos, et al.
Publicado: (2023) -
Sterile Endophthalmitis after Intravitreal Injections
por: Marticorena, Joaquín, et al.
Publicado: (2012) -
Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections
por: Levin, Ariana M, et al.
Publicado: (2017)